Bosutinib shows ‘low’ vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia.
Source: MedWire News - Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news